Hemispherx Biopharma (HEB -21.2%) gets slammed today after saying the FDA's Arthritis Advisory...

|About: Hemispherx Biopharma, Inc (HEB)|By:, SA News Editor

Hemispherx Biopharma (HEB -21.2%) gets slammed today after saying the FDA's Arthritis Advisory Committee has shot down its New Drug Application for the marketing of Ampligen for chronic fatigue syndrome by a 9-4 vote, with one abstention. The agency said that, considering the totality of the data, there wasn't sufficient evidence of Ampligen's safety or treatment efficacy.